Quanterix Corporation (QTRX)
NASDAQ: QTRX · IEX Real-Time Price · USD
12.72
+0.04 (0.32%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Quanterix Revenue
Quanterix had revenue of $125.98M in the twelve months ending March 31, 2024, with 20.64% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $32.07M with 12.69% year-over-year growth. In the year 2023, Quanterix had annual revenue of $122.37M with 15.96% growth.
Revenue (ttm)
$125.98M
Revenue Growth
+20.64%
P/S Ratio
3.86
Revenue / Employee
$285,664
Employees
441
Market Cap
486.80M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 122.37M | 16.85M | 15.96% |
Dec 31, 2022 | 105.52M | -5.03M | -4.55% |
Dec 31, 2021 | 110.56M | 24.18M | 27.99% |
Dec 31, 2020 | 86.38M | 29.64M | 52.25% |
Dec 31, 2019 | 56.73M | 19.10M | 50.76% |
Dec 31, 2018 | 37.63M | 14.76M | 64.52% |
Dec 31, 2017 | 22.87M | 5.29M | 30.08% |
Dec 31, 2016 | 17.59M | 5.41M | 44.38% |
Dec 31, 2015 | 12.18M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionQTRX News
- 15 days ago - Quanterix to Participate at the Scotiabank Healthcare 1x1 Day - Business Wire
- 27 days ago - Quanterix to Present at 45th Annual Goldman Sachs Global Healthcare Conference - Business Wire
- 5 weeks ago - Quanterix to Present at Leerink Partners Healthcare Crossroads Conference 2024 - Business Wire
- 2 months ago - Quanterix Releases Financial Results for the First Quarter of 2024 - Business Wire
- 2 months ago - Quanterix To Report First Quarter 2024 Financial Results - Business Wire
- 3 months ago - Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer's Disease Testing Infrastructure - Business Wire
- 4 months ago - Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer's Disease - Business Wire
- 4 months ago - Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023 - Business Wire